Jessica A. Miller, Patricia A. Thompson, Iman A. Hakim, Ana Maria Lopez, Cynthia A. Thomson, Wade Chew, Chiu-Hsieh Hsu, H.-H. Sherry Chow Mel & Enid Zuckerman College ...

A Peter Mac-led international clinical trial has shown adding an immunotherapy drug to the chemotherapy that patients receive ...

Dr. Maxwell Lloyd shared the importance of improving patient access to innovative therapies like Orserdu at the 2024 San ...

Maintaining treatment with CDK4/6 inhibitors significantly suppresses the growth of breast cancer cells, even after drug resistance has developed, according to new research.

A far shorter, simpler, and less toxic treatment protocol for patients with triple-negative breast cancer produced outcomes ...

Scientists have developed a single-dose treatment for breast cancer that eliminates small tumors and significantly shrinks larger ones without side effects. Named ErSo-TFPy, this drug shows ...

The response of ER+/HER2– breast cancer to treatment varies widely, which not only affects clinical outcomes but can pose a challenge to the effective medical management of the condition.

Limited to estrogen receptor-positive breast cancer (ER+) the compound addresses many common concerns with existing treatment ...

Jan. 22, 2025 — Despite significant therapeutic advances, breast cancer remains a leading cause of cancer-related death in women. Treatment typically involves surgery and follow-up hormone ...

The company emphasizes its commitment to providing safer and more tolerable treatment options for breast cancer patients. With analyst price targets ranging from $4 to $7 per share and an overall ...

Researchers say lerociclib plus fulvestrant could become a new treatment option for HR+/HER2- advanced breast cancer, but lerociclib is not approved in the US.